Detail of the clinical trial

Title of the trial A randomized, open-label, multicenter, phase II/III study to evaluate the safety and efficacy of Lumiliximab in combination with Fludarabine, Cyclophosphamide and Rituximab versus Fludarabine, Cyclophosphamide and Rituximab alone in subjects with relapsed chronic lymphocytic leukemia.
EudraCT number 2006-002987-24
Protocol number 152CL201
Sponsor Biogen Idec., Ltd., Velká Británie
Indications Hemato-oncology
Diagnosis relapsed chronic lymphocytic leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2008
Date of approval by Institute (SÚKL) 31.07.2008
Date of approval by EC 21.08.2008
Date of initiation CT in ČR 22.10.2008
Date of ending CT in ČR 22.02.2010
Notice
Sites Interní hematoonkologická klinika, FN Brno - Bohunice
Odd.klinické hematologie FN KV, Praha 10 (discontinued)
II. Interní klinika - odd.klinické hematologie, FN Hradec Králové
I. Interní klinika VFN, Praha 2

‹‹ Back to list